Method for maximizing coronavirus killing activity of high-density lipoproteins, and pharmaceutical composition for preventing or treating covid-19
AssigneeRaydel Korea Co., Ltd.
InventorKyung-Hyun CHO
Life of this patent
Estimating the term…
Loading patent…
AssigneeRaydel Korea Co., Ltd.
InventorKyung-Hyun CHO
Estimating the term…
The present invention relates a method for maximizing the coronavirus killing activity of high-density lipoproteins, and a pharmaceutical composition for preventing or treating COVID-19. As identified by the present inventors, non-glycated normal high-density lipoproteins (HDLs) exhibit killing activity against coronavirus (SARS-Cov-2) that is superior to that of glycated HDLs, and thus a pharmaceutical composition for preventing and treating COVID-19, containing non-glycated native HDLs as an active ingredient, is provided. In addition, the present invention is useful since a method for maximizing the coronavirus killing activity by using an HDL glycation inhibitor, on the basis of the identification by the present inventors, can be provided and a method for screening for a pharmaceutical composition for preventing and treating COVID-19 by evaluating the degree of HDL glycosylation inhibition of candidate drugs can be provided.
A pharmaceutical composition for preventing and treating corona 19 infection (COVID-19) comprising HDL (high-density lipoprotein) and an HDL glycation inhibitor as active ingredients.
(canceled)
A method for maximizing coronavirus killing activity of HDL (high-density lipoprotein), said method comprising administering HDL with an HDL (high-density lipoprotein) glycation inhibitor.
(canceled)
A method for screening a pharmaceutical composition for preventing or treating corona 19 infection (COVID-19) consisting of the following steps:
A method for predicting prognosis of corona 19 infection (COVID-19) consisting of the following steps:
Dependencies are inferred from the claim text.